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dKey concepts
n Many vaccines are comprised of whole viruses or bacteria and therefore contain many, often poorly deﬁned,
antigens as well as other microbial molecules important in triggering innate and/or adaptive immune responses
n Where the whole pathogen approach is not feasible or desirable, other approaches are considered, such as
subunit antigens that are naturally derived or generated using recombinant DNA technology
n Vaccines containing fewer deﬁned antigens may be less reactogenic but also less immunogenic thus
necessitating the inclusion of adjuvants
n Key pathogen virulence determinants usually make excellent antigens for inclusion in vaccines, eg viral ligands
such as haemagglutinins or inactivated bacterial toxins
n The ﬁnal choice of antigen is often determined by what is achievable immunologically and technologically, and
what is optimal from a safety perspective
n An immunogen is an antigen capable of inducing an adaptive immune response; an epitope is the highly
speciﬁc structure or site on an antigen that is recognised by either the surface B-cell receptor, T-cell receptor
or soluble antibody2011 Elsevier B.V.
oi:10.1016/j.pervac.2011.05.003
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62 UNDERSTANDING MODERN VACCINESVaccine antigens include whole live pathogens (modiﬁed to reduce
their virulence), individual pathogen components (eg protein or
polysaccharides) and the genetic material of the pathogen (ie
‘naked’ DNA/RNA) which can direct the production of the vaccine
antigen in the recipient.
The earliest vaccine consisted of infected ﬂuid derived from people
infected with cowpox, which was used by Edward Jenner to prevent
the signiﬁcantly more serious human disease of smallpox. What
Jenner did not know was that the infected ﬂuid used contained live
cowpox virus. Cowpox virus shares antigenic components with
smallpox, but is much less virulent or pathogenic in humans.
Consequently, vaccinees developed immunity to smallpox without
the risk of serious disease. Subsequent empirical observations in
the 19th century noted that pathogens with reduced virulence and
even dead pathogenic bacteria also acted as vaccines. This
breakthrough allowed the development of attenuated and
inactivated whole-pathogen vaccines, pioneered by the work of
Louis Pasteur and Robert Koch. A paradigm shift occurred in the
late 19th and early 20th centuries as a result of progress in
biochemistry and the development of vaccines based on toxins, or
their inactivated derivatives, the toxoids (Figure 3.1). The realisation
that the whole pathogen was not always needed to induce
immunity, and the subsequent concept of ‘antigen’, were essential
to improvements in the safety and efﬁcacy of prophylactic vaccines.
It is important to note that most vaccines in this period were
successfully developed in the absence of a solid understanding of
the immunological responses induced by vaccines or key physical
structures of the targeted pathogens. Today, a better understanding
of hostepathogen interactions and of the key features needed to
induce a proper immune response allows for a more scientiﬁc
(rational, hypothesis-based approach), rather than empirical
(trial and error), approach to the choice and deﬁnition of the
target antigen(s).
Figure 3.1 Vaccines and technologies. Vaccine development timeline from the ﬁrst practice of variolation e deliberate infection of humans
with material derived from human smallpox pustular material. Most of the other technologies are still used for the development of vaccines.
Plasma-derived vaccines have not been used in most countries since the 1990s.
HPV, human papillomavirus; Hib, Haemophilus inﬂuenzae type b; OPV, oral polio vaccine; IPV, inactivated polio vaccine.
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64 UNDERSTANDING MODERN VACCINESAntigen discovery and deﬁnition
In the late 19th and early 20th centuries, bacterial constituents were
deﬁned as ‘antigen’, and later as ‘immunogen’. Paul Ehrlich
formulated the theory that physiologically active substances
interacted with speciﬁc receptors in the blood and introduced the
concept of antigens (‘antibody generators’) as the ligands of
antibodies. This idea was developed from his work on
toxineantitoxin complexes in sera, and the ﬁrst recognition of
antibodies in 1890. An antigen may be deﬁned as the target of an
immune response e this may be an innate or adaptive response.
How the immune system receives the information around the
antigen is extremely important as well. The receptors of Tand B cells
speciﬁcally recognise limited and unique parts of an antigen
molecule during an adaptive immune response; therefore the
selection of the appropriate antigen is central to vaccine design. In
addition to these speciﬁc antigenic components, there are several
other types of pathogen constituents that are essential to the
induction of innate and subsequent adaptive immune responses,
which may be considered as ‘defensive triggers’. These are needed
together with the antigenic structure to activate the immune
response (see Chapter 2 e Vaccine immunology).Identifying and producing
vaccine antigens
The identiﬁcation of vaccine antigens can vary in complexity
depending on whether the whole pathogen or pathogen-derived
material is involved (Figure 3.2). Pathogen-based approaches to
vaccine antigens can vary in terms of the complexity of the material
they contain. This may include the use of whole viruses or bacteria,
in the form of reassortant, attenuated or inactivated microbes.
Attenuated pathogens remain live and replication-competent but
are altered in some way to reduce their virulence in the target host;
inactivated pathogens are dead, or in the case of viruses
inactivated, eg unable to replicate; reassortant pathogens are
a subtype of attenuated organisms, containing genetic material
Figure 3.2 Approaches to vaccine antigen selection.
Whole pathogen-based vaccines need to undergo
attenuation or inactivation processes, while subunit
vaccines rely on puriﬁed fractions of pathogens derived by
physical disruption of whole organisms.
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and will express proteins derived from all component strains. Where
whole-pathogen approaches are not feasible, other approaches,
such as the use of split, subunit or recombinant antigens, will be
considered. The choice of antigen is determined by what provides
optimal outcomes in terms of safety and immunogenicity, and also
by what is achievable by the standards of technology.
Figure 3.3 Recombinant/DNA approaches to vaccine
antigens. Protein antigens are produced using
recombinant DNA technology, where the DNA
sequence coding for the antigenic protein is inserted
into an expression system that is then able to produce
large quantities of that speciﬁc antigen in vitro (panel
A) or following administration to the host, eg using
a DNA plasmid (panel B) or a live vaccine vector
(panel C) as the expression system.
66 UNDERSTANDING MODERN VACCINESFurther approaches to vaccine antigens may include recombinant
DNA techniques (Figure 3.3), where the gene encoding the
antigen is isolated and either expressed and puriﬁed from
a protein-production system (eg yeast or insect cells) (Figure 3.3,
panel A), or is expressed directly by the vaccine recipient following
injection of an engineered plasmid (Figure 3.3, panel B) or a live
vector (Figure 3.3, panel C). DNA-based candidate vaccines are
in the earlier stages of development compared with their
pathogen-based counterparts.
An experimental approach to vaccine peptide synthesis involves the
direct joining of short fragments of peptides (molecules consisting
of two or more amino acids) to form a complete antigen containing
multiple epitopes from pathogen proteins (Figure 3.4). This can
then be puriﬁed out from any truncated or incorrectly formed
peptide segments, giving a pure and highly speciﬁc antigen. The
beneﬁt of such an approach is that it facilitates the generation of
recombinant peptides that contain elements of antigenic proteins’
conformational epitopes in a concatenated form (recognised
by B cells) and linear epitopes (recognised by T cells).
Figure 3.4 Peptide approaches to vaccine antigens. Recombinant peptide technology facilitates the generation of vaccines containing peptides
that combine linear and elements of non-linear epitopes. Such vaccines are capable of stimulating an immune response from both B and T cells.
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68 UNDERSTANDING MODERN VACCINESIn every circumstance, the principle is to keep the antigenic
structure or component of the pathogen intact and to eliminate
most or all of the irrelevant and especially reactogenic features.
DNA vaccines move the concept a step further, by using
only selected genetic material from the pathogen, contained within
an ‘expression cassette’ present within a small non-replicating
piece of circular DNA. The antigen is then produced by cells
of the vaccine recipient, which take up the injected DNA
segment, allowing for direct production of the antigen in situ by
the recipient.
Most of the possible approaches to the development of
pathogen-derived vaccines are still in use, including whole
inactivated and live attenuated, subunit and split pathogens, with
and without adjuvants. DNA-based candidate vaccines are in
earlier stages of development, although recent preclinical animal
data for some pathogens have been promising.Whole live, attenuated and killed/
inactivated pathogen vaccines
The most direct method for developing a vaccine is to use
a whole pathogen, either killed/inactivated or attenuated (live
but rendered harmless). These complete organisms are likely to
contain all of the relevant pathogen-speciﬁc protein and
carbohydrate antigens for effective vaccination and all or some of
the innate defensive triggers that exist in the virulent pathogen.
Moreover, live pathogen vaccines replicate and disseminate
to their target tissue in a pattern similar to that occurring during
a natural infection. The higher intensity of the innate immune
responses, higher antigen content following replication and
the more prolonged antigen persistence are the presumed
mechanisms of how, generally, live, attenuated vaccines
stimulate an effective and long-lasting immunity. Consequently,
whole-pathogen vaccines can be highly effective and, if the
pathogen can be grown quickly in cell culture, relatively easy to
produce. A whole-pathogen vaccine can potentially be tested
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without the development time associated with identifying and
generating antigenic subunits, such as recombinant proteins
or peptide epitopes. However, whole-pathogen vaccines are
not a viable option for microorganisms which do not grow
efﬁciently in cell culture, such as hepatitis B virus (HBV); or at all
in ex vivo culture, for example Mycobacterium leprae. Several
reasons why this approach may not be used either for speciﬁc
pathogens or for vaccines intended for certain populations are
discussed below.LIMITATIONS OF THE WHOLE-PATHOGEN APPROACH
Loss of attenuation of live vaccines
Most live, attenuated vaccines undergo (limited) replication within
host cells, which is problematic for some populations. If the
restriction of growth of the attenuated organism is dependent, for
example, on the presence ofCD4þ Tcells, vaccination of people with
human immunodeﬁciency virus (HIV)/acquired immunodeﬁciency
syndrome (AIDS) may lead to serious infection/disease by the
normally attenuated organism. For this reason, live, attenuated
vaccines, such as the Bacille CalmetteeGuérin (BCG) vaccine, are
contraindicated in most immunocompromised people.
High reactogenicity
Some inactivated whole-pathogen vaccines are associated with
high-frequency local or systemic reactogenicity. This reactogenicity
is likely due to the potency of other microbial molecules that
trigger the innate immune response. Two well-known examples of
inactivated vaccines associated with high reactogenicity were the
whole-cell pertussis vaccine and the ﬁrst inactivated whole-virus
inﬂuenza vaccine. In some countries, the reactogenicity proﬁle of
the vaccine produced a very low parental acceptance for infants
and children, promoting the development of alternatives such as
the subunit acellular pertussis vaccines and the split/subunit
inﬂuenza vaccines.
70 UNDERSTANDING MODERN VACCINESUnwanted immune response
Unwanted and unexpected immune effects were observed with the
ﬁrst formalin inactivated respiratory syncytial virus (RSV) vaccine,
developed in the 1960s. This inactivated whole-virus vaccine caused
enhanced pulmonary pathology upon subsequent natural exposure
of vaccinees to RSV compared with that seen in unvaccinated
individuals (Kim et al., 1969). The root cause of this adverse effect is
still not fully understood. One hypothesis is that the formalin
treatment altered the structure of the protective antigens, resulting in
the production of non-protective immunity. This hypothesis is
supported by the ﬁnding that the vaccinees generated
non-neutralising antibodies against the F and G proteins, which may
have resulted in a delayed clearance of RSV from the lungs. More
recently, a study showed that the exaggerated responsemight bedue
to low antibody avidity for protective epitopes (Delgado et al., 2009).
Risk of reversion
There is a small but calculable risk that attenuated pathogens, for
example the oral polio vaccine, can reacquire the virulent genotype. In
deletion mutants, this could occur through gene recombination with
related microbes, replacing missing virulence genes in the vaccine
strain. In ‘culture-attenuated’mutants,whichdiffer genetically from the
natural pathogen because of the presence of sequence mutations
that may involve a single nucleotide, random ‘back mutations’ could
lead to the reactivation of silenced virulence genes. The history of use
of live attenuated vaccines has shown thatmost of these vaccines are
safe and that the risk of reversion is more theoretical than real.
Pathogen complexity
Pathogens are not only antigenically complex, but antigenic
composition may change during their life cycle. Pathogens may
also have complicated disease-causing pathways, involving
multiple host tissues. For example, in some diseases, multiple
different antigens are produced over different phases of the
pathogen life cycle. These factors mean that different antigens
would be protective against different stages of infection. A good
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undergoes several stages of development, each of which is
antigenically distinct from other stages, and which occur in different
anatomical locations. This makes it difﬁcult to target all of the critical
phases of the infective process using the whole pathogen from any
single stage of development. This is one of the key challenges to
producing an effective malaria vaccine. (It is not the only challenge
as the immunodominant antigenic site is also subject to ‘segment’
mutation as different protein ‘cassettes’ are inserted at this site.)
Latency and immunoevasion
Some pathogens exist in a latent state within the host, often for the
life of the host, or may be protected or hidden from the immune
system and are, therefore, not available to the vaccine-induced
immune response. Latency is a feature of bacteria, such as
Mycobacterium tuberculosis (the causative agent of tuberculosis),
and herpesviruses, such as cytomegalovirus (CMV), varicella zoster
and herpes simplex viruses. In addition, some pathogens produce
virulence factors that actively suppress or subvert host immunity, for
example CMV produces proteins that can subvert or evade killing of
infected cells by natural killer cells. In this case, vaccine formulation
should consider alternative options to a whole-pathogen approach,
to try to improve on nature.
Reduced immunogenicity
Research in antigen development has been driven by the reduced
immunogenicity sometimes observed with highly attenuated or
killed pathogen antigens. The procedure for attenuation or
inactivation of the pathogen may remove vital defensive triggers,
but could also remove/alter essential protective immunogenic
components (epitopes) present in the intact pathogen, in which
case the remaining antigens may not induce immune responses
that protect the vaccine recipient against the live pathogen. An
example of this is the live attenuated Towne vaccine strain of CMV
which, although providing some protection against CMV disease in
certain settings, is actually less protective than immunity that is
TABLE 3.1. CHARACTERISTICS OF LIVE AND KIL
Live attenuated
Examples: OPV, MMR, VZV, some inﬂuenza, BCG
Mimic the natural infection and retain most defensive trigge
elements; however, may retain immune evasion factors
Strong priming usually achieved with 1e2 doses
Long-term persistence of immunity
May induce some mild disease symptoms
Rare revision to virulence; unsuitable for immunocompromis
Potential for immunological interference with other live vacc
Less stable over time, heat labile
Response affected by recent administration of blood/blood-d
or presence of maternal antibody in an infant
OPV, oral polio vaccine; MMR, measles, mumps and rubella
severe forms of tuberculosis); IPV, inactivated polio vaccine;
72 UNDERSTANDING MODERN VACCINESacquired naturally following recovery from CMV infection (natural
immunity). This strain may have been over-attenuated by multiple
(>125) passages through human cell culture, rendering it
suboptimally efﬁcacious as a vaccine.
Overall, however, when used in vaccines, whole live, attenuated
pathogens are highly immunogenic, since both antigenic structures
and defensive triggers, which activate the innate immune system (see
Chapter 2 e Vaccine immunology) are present. Some of the relative
advantages and disadvantages associated with live, attenuated
and killed/inactivated vaccines are summarised in Table 3.1.
In order to address the above limitations of using a whole-cell
pathogen approach, research has moved to deﬁne individual, or
combinations of, pathogen-derived components that could be used
instead as vaccine antigens. As mentioned previously, one of the
ﬁrst reasons to look for sub-cellular components was prompted by
the high reactogenicity of some older whole-pathogen vaccines.
This search has produced a new category of vaccines, the
so-called split/subunit vaccines.LED VACCINES
Killed/inactivated
Examples: IPV, HAV, whole-cell pertussis
rs/immunogenic Usually require adjuvants due to reduced immunogenicity/
missing defensive triggers
Multiple doses usually needed for priming
Booster doses may be needed to maintain long-term immunity
Do not induce disease symptoms
ed patients No risk of reactivation, non-infectious
ines Low risk of immunological interference
Relatively stable over time, better resistance to cold
chain deviation
erived products Generally not affected by administration of blood/
blood-derived products
vaccine; VZV, varicella zoster virus vaccine; BCG, Bacille CalmetteeGuérin (against
HAV, hepatitis A virus vaccine.
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Split-pathogen and subunit antigens are derived from physical
separation and/or fractionation of the whole pathogen into
smaller components with pieces of the viral envelope and surface
antigens present in the antigen mix. There are various means of
achieving this, including mechanical and chemical disruption.
Among licensed vaccines, the majority use a subunit approach;
inﬂuenza vaccines are currently the only vaccines to use a
split-pathogen approach.
The toxoid-based vaccines of the early 20th century were the ﬁrst
subunit vaccines, although they were based on generating
antibody to a disease-causing product of the pathogen rather than
a structural component of the pathogen. Tetanus and diphtheria
toxoid vaccines are designed not to prevent infection, but to elicit
antibodies that bind and neutralise the bacterium’s key exotoxin,
since the toxins are responsible for the clinical symptoms of
the disease.
More complete vaccine protection may be afforded using
a combination of different subunit antigen components. Some
acellular pertussis vaccines that comprise several subunit
antigen components (eg pertussis toxoid, pertactin, ﬁlamentous
haemagglutinin [FHA]), each of which provides limited protection,
have demonstrated that multiple subunits can be combined to
create an efﬁcacious, well-tolerated vaccine.DEFINING SUBUNIT ANTIGENS
Puriﬁed subunits are antigenic proteins or polysaccharides,
isolated from viral or bacterial structures and components. There
are two broad approaches to determine which subunit antigens
should be included in a vaccine. The classical approach is to
study, in detail, the relationship between a pathogen and its host in
order to identify the key virulence determinants that the pathogen
requires for host entry, survival and/or dissemination to cause
symptomatic disease. By mutating/deleting the genes encoding
these virulence determinants and retesting the mutant pathogen in
Figure 3.5 Reverse vaccinology approach. In the search f
genome to genes encoding putative surface-exposed or exp
candidates are expressed in recombinant form, puriﬁed an
performed on the protective antigens in a search for antige
validated in animal models before moving into human clinica
74 UNDERSTANDING MODERN VACCINESan infection model, the importance of the individual determinant
can be established.
The individual virulence determinant identiﬁed by the molecular
postulates (which can be a protein or carbohydrate, eg capsule
polysaccharide) is then puriﬁed and tested as a possible
vaccine antigen.
An alternative approach is based on identifying the type of
pathogenic structures that are most likely to be important
immunogens according to their structural signature or physical
location within the pathogen. Surface proteins of the viral envelope
or viral capsid proteins can be good antigen candidates, although
this is not so straightforward when the pathogen is a bacterium or
a parasite, which may possess many hundreds of surface or
secreted proteins. Advances in immunology, molecular biology
and, especially, genomics and bioinformatics have made it possible
to identify individual antigenic structures through computer-based
searches of the pathogen’s genome. This technique is known as
‘reverse vaccinology’ (Figure 3.5).or vaccine candidates, the ﬁrst level of reﬁnement from all genes in the pathogen
orted proteins is algorithm based, using prediction software (1). Identiﬁed vaccine
d used as a vaccine in a suitable animal model (2). Complete epidemiology is
nic variation (3). Invariant/least variant proteins or combinations thereof are further
l trials (4).
TABLE 3.2. CHARACTERISTICS OF SPLIT
AND SUBUNIT VACCINE APPROACHES
Highly focused, speciﬁc response
Reduced immunogenicity and potential for escape
mutants (pathogens that develop mutations resistant to
the immunological protection conferred by vaccination)
Non-infectious
Low reactogenicity
No or limited availability of innate defensive triggers
Acceptable tolerability
Adjuvants normally required to compensate for lower
immunogenicity
Synthetic production may be possible, facilitating
supply (compared with whole pathogen)
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technology can identify genes that encode proteins with sequence
characteristics, which suggest they are secreted or expressed on
the surface of a pathogen. These genes can be isolated (ie the
genes are ‘cloned’) and the proteins expressed in recombinant form
in appropriate cells in culture. The proteins can then undergo testing
as vaccine antigens in animals, singly or in pools. Those that are
most immunogenic, or which stimulate protection in animal models,
are selected for further laboratory development and preclinical
testing. The technique may also require the testing of a large
number of potential vaccine antigens that must be evaluated in
a validated testing system, eg using an animal model that predicts
how humans will respond. As additional checks, sera from the
animal model or infected humans can be used to test in vitro
neutralisation of virulence, ie to authenticate folding of the
recombinant protein, or in passive transfer experiments to show that
protection is antibody mediated, ie to deﬁne the correlate of
immunity/protection.
Limitations of the subunit approach
A limitation of the subunit approach is that a cell culture-synthesised
protein may not correctly form the three-dimensional structure that it
assumes in the host, and may not induce protective antibodies. In
addition, subunit vaccines often elicit weaker antibody responses
than other types of vaccines, because of the lack of innate
defensive triggers that drive the innate immune system.
Carbohydrate residues on antigenic proteins inﬂuence antibody
binding, however, bacterial expression systems do not usually
glycosylate recombinant proteins in a manner comparable to
mammalian cells. Expression systems are, therefore, being
continually improved to allow the production of glycoproteins that
more accurately resemble a pathogen protein’s native
conformation.
The characteristics of split and subunit vaccine approaches
compared with whole-pathogen approaches are provided in
Table 3.2.
Innate ‘defensive triggers’ may be
conserved molecular structures, such as
repeating units of carbohydratemoieties,
certain nucleic acid sequences, or
molecules that are recognised by
specialised pathogen receptors on innate
immune cells and certain other cell
types. The activation of immune defence
mechanisms requires the presence of
both antigen and defensive triggers to
communicate the nature of the potential
threat and to induce adequate immune
responses. These elements may be
missing in subunit and recombinant
vaccine antigens and, for that reason, the
addition of adjuvants and/or alternative
ways of helping the antigens to stimulate
the immune system are needed.
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PEPTIDE ANTIGENS
Antigens generated by recombinant DNA technology
Improvement of industrial processes and sophisticated analytical
methods allow us to take the concept of subunit vaccines a step
further. HBV and human papillomavirus (HPV) vaccines are concrete
examples of this approach. Speciﬁc antigenic proteins can be
produced by recombinant DNA technology for viruses such as HBV
and HPV that do not grow in cell lines. This approach also optimises
the efﬁciency of the manufacturing process and the purity of the
antigen (Figure 3.6). The gene encoding the speciﬁc protein of
interest can be inserted into an expression system, eg a baculovirus,
which is used to infect insect cells, or into yeast cells. Scalable
production systems, such as yeast or baculovirus/insect cells,
produce large quantities of the recombinant protein, which is
harvested and puriﬁed. As the pure antigen is not accompanied by
any of the elements that activate the defensive triggers of the innate
immune system that would be present in the native pathogen, this
approach results in an antigen that is well tolerated, but
usually requires the addition of an adjuvant in order to achieve high
immunogenicity and long-term protection.
A peptide antigen approach represents an additional step to the
protein antigen approach. Peptide antigens may prove beneﬁcial
in the context of diseases where the pathogen evolves and
protective antigens are numerous. In this setting, mixtures of
different peptides known to be targets for protective immunity
can be used more efﬁciently than producing many different
full-protein antigens.Direct synthesis of short peptide antigens
It is possible to identify and directly synthesise by various methods
speciﬁc peptides that elicit adaptive immune responses. The
peptides selected for vaccine development must contain epitopes
that induce sufﬁcient priming of naïve T cells to attain effective
cellular and humoral immunity.
Figure 3.6 HPV L1 synthesis in a yeast expression
system. Antigens can be produced using cellular
expression systems. In the case of HPV L1 synthesis, the
DNA encoding the L1 capsid protein from the HPV virus is
inserted in the genome of yeast cells. Yeast cells then
express high levels of recombinant capsid proteins. These
are extracted from the yeast cell and puriﬁed. The L1
proteins aggregate to form pentamers, which then
self-assemble into empty viral capsids. These VLPs form
the antigenic component of HPV vaccines.
HPV, human papillomavirus; VLP, virus-like particle.
Figure 3.7 Types of inﬂuenza vaccine. The vaccines
produced to combat inﬂuenza encompass most of the
current approaches to antigen selection. Inﬂuenza
vaccines therefore include attenuated and whole-virus
antigens as well as split or subunit pathogen approaches.
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CASE STUDY 1 Antigens for inﬂuenza vaccines: a variety of approaches to satisfy
changing needs
Inﬂuenza vaccine technology encompasses most of the current approaches to antigen
selection, including the use of whole viruses (Figure 3.7). The natural immune response to
inﬂuenza viruses involves both humoral and cell-mediated immunity and the type-1 interferon
response that is important for viral clearance. The humoral immune response is normally of
more importance after viral clearance, and antibody responses associated with the
immunoglobulin (Ig) G and IgA isotypes are important for protection against reinfection or
infection with a new strain. Antibody against the haemagglutinin (HA) protein (a glycoprotein
responsible for binding the virus to host cells) is considered the primary immune mediator of
protection as this can inhibit virus binding to the epithelium, and thus block the early stages of
infection. Antibody to the neuraminidase (NA) protein has also been considered as it can
prevent cell-to-cell spread of the virus within the host. The evaluation of haemagglutinin
inhibitory (HI) antibody titres has been used from the very beginning to assess inﬂuenza
vaccine immune-protective abilities.
Seasonal inﬂuenza vaccines
The ﬁrst seasonal inﬂuenza vaccines were based on live, attenuated viruses and produced in
the 1940s. These vaccines were genetically prone to instability, resulting in variable degrees
of attenuation and cases of inﬂuenza infection in some vaccinees. For this reason, this
approach was abandoned in favour of inactivated whole formulations. Also ﬁrst developed
during World War II, killed whole-virus vaccines were immunogenic, but remained quite
reactogenic, especially in children, where high rates of fever were recorded. This prompted
the search for subvirion vaccines. Although whole-cell vaccines are still in use today in some
countries, the majority of inﬂuenza vaccines manufactured over the last 30e40 years have
been based on subunit and split-virus formulations, developed to minimise reactogenicity.
These antigens consist of inﬂuenza fragments of varying degrees of purity. Some vaccines of
this type are puriﬁed sub-virus particles (split vaccines), whereas others are based on highly
selected and puriﬁed virus proteins or proteins produced from recombinant systems (subunit
vaccines). The tolerability proﬁle of these puriﬁed antigens is better than that with
whole-pathogen vaccines, and their immunogenicity has been satisfactory. One dose of the
vaccine is enough for the adult population, probably due to previous exposure to inﬂuenza,
while two doses of split/subunit vaccines are needed in young children since most of them are
naïve to inﬂuenza infections.
An ongoing challenge with seasonal inﬂuenza vaccines that continues to drive vaccine
research is limited immunogenicity in the elderly. This is due to the natural process of
Continued on next page
78 UNDERSTANDING MODERN VACCINES
immunological senescence e a declining ability of the immune system to mount effective
immune responses with increasing age. One of the approaches to solving this problem is the
use of adjuvants and two seasonal inﬂuenza vaccines, one adjuvanted with an oil-in-water
emulsion and the other with a virosome (based on liposome), which became available in
Europe in the 1990s. The adjuvanted vaccine improves immune responses in the elderly
compared with the traditional non-adjuvanted vaccine.
Also in the 1990s, research on live, attenuated inﬂuenza vaccines experienced a resurgence
as techniques, such as targeted gene deletions and reassortment of related strains, made it
possible to produce vaccine strains with speciﬁc characteristics. These included
cold-attenuated strains that were unable to replicate in the warm (core body temperature)
environment of the lungs. This approach permitted the development of a trivalent cold
adapted inﬂuenza vaccine ﬁrst licensed in the USA in 2003 and currently approved for
healthy children older than 2 years and adults less than 50 years of age. This vaccine,
which is delivered intranasally, is updated with new reassortant strains each year to
protect against seasonal inﬂuenza and is capable of inducing strong immune responses
in children.
Pandemic inﬂuenza vaccines
Pandemic inﬂuenza presents unique challenges not seen with seasonal inﬂuenza,
particularly the lack of pre-existing immunity in much of the population, which translates to
the need for an even higher number of vaccine doses in a short space of time. In
a pandemic setting, rapid protection following vaccination is desirable. Due to the special
circumstances surrounding an inﬂuenza pandemic, vaccine manufacturers, regulatory
bodies and health authorities approached the development of pandemic inﬂuenza
vaccines in many ways. All known formulations were tested as pandemic candidate
vaccines, including live attenuated and killed whole-virus vaccines, plus split-virion/
subunit vaccines; the addition of adjuvants was also considered to reduce the amount
of antigen in the vaccine, ie dose-sparing to maximise vaccine availability. Many of these
vaccines were licensed for use in children, adults and the elderly during the 2009e2010
inﬂuenza pandemic. The adjuvanted split/subunit vaccines provided high levels of
neutralising antibodies, exceeding the levels of antibody required by the licensing
authorities in Europe and the USA with an important reduction of the antigen content and
therefore offering the possibility to vaccinate more people. Overall, the live attenuated,
whole killed and adjuvanted subunit pandemic inﬂuenza vaccines were immunogenic and
well tolerated, and were made available in many parts of the world relatively quickly (see
Chapter 5 e Vaccine development).
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In response to the notion that inﬂuenza
vaccines cause inﬂuenza-like symptoms,
randomised, blinded studies have been
performed in which trial volunteers were
divided into two groups: inﬂuenza
vaccine and placebo (Nichol et al., 1995).
The only differences in symptoms
between groups were increased
soreness in the arm and redness at the
injection site among those who received
the inﬂuenza vaccine. There were no
differences in terms of body aches, fever,
cough, runny nose or sore throat.
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We can use our understanding of immunology and the
interactions between host and pathogen in order to manipulate
antigens to make them more immunogenic for vaccines. This is
especially relevant for weakly immunogenic antigens, such as
macromolecules consisting of repeating structural units (eg
polysaccharides), and antigens that are most immunogenic when
presented as part of larger molecules.f polysaccharide antigens to broaden the immune
nd to have several common properties; they are generally foreign to the
tein to drive T helper responses, are of high molecular weight (ie are
and chemically complex. The degree to which each of these characteristics
lecule determines how antigenic it is under given circumstances, and how
es immune responses. Some species of bacteria (such as all of those that
are enclosed within polysaccharides forming bacterial capsules. While they
mplex macromolecules, polysaccharides are composed of repeating
t lack the ability to recruit T cells, which means that, chemically, they are
nd hence are weakly antigenic. On exposure to encapsulated bacteria, the
ell response that should be provided by helper T cells, and which leads to
mory and highly potent response, is not optimally induced (Figure 3.8).
lysaccharide antigens do not contain T-cell epitopes and are not presented
ting cells (APCs) to T cells. Bacterial capsular polysaccharides therefore
thymus-independent B-cell responses and are typically recognised by
B cells. These cells can produce short-lived responses, if the repeated
tigen can cross-link the speciﬁc B-cell receptor Ig, but such responses are
quickly wane.
re particularly unresponsive to capsular polysaccharide antigens. The
e poorly understood, but may be due to the immaturity of the immune and
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complement systems, and lack of a large enough pool of B cells to allow for clonal expansion
(see Chapter 2 e Vaccine immunology). Although in adults there is an increased ability to
respond to these antigens, the problem of frequent revaccination due to limited or absent
induction of immune memory remains an important issue.
Bacterial infections by pathogens, such as Haemophilus inﬂuenzae type b (Hib), Neisseria
meningitidis and Streptococcus pneumoniae, are responsible for the vast majority of bacterial
meningitis cases. The polysaccharide capsules of encapsulated strains of these bacteria are
a major virulence factor and deﬁne distinct serotypes within each species. Many of the most
severely affected victims of these infections are young children, who cannot mount effective
immune responses against encapsulated bacteria, and are at high risk of death or serious
permanent consequences if not promptly treated with appropriate antibiotics. Vaccines
against these pathogens based on puriﬁed polysaccharide components have a limited
protective effect in adults and older children, but are poorly immunogenic in young children.
Revaccination every few years is also needed regardless of age because of the vaccine’s
inability to induce immune memory.
The solution to this problem was the development of conjugate vaccines, where capsular
polysaccharides are covalently linked to protein carriers known to be very immunogenic. This
principle was ﬁrst applied to Hib vaccine, and proved to be highly effective. Subsequently,
other bacterial conjugate vaccines were developed for pneumococcal and meningococcal
pathogens. Proteins used as conjugate carriers include tetanus and diphtheria toxoids,
and protein D of non-typeable Haemophilus inﬂuenzae. The surface B-cell receptor of
a polysaccharide-speciﬁc B cell binds to the polysaccharide component, triggering the ﬁrst
stages in the activation process. The protein toxoid components of these conjugates are
then internalised and presented to speciﬁc T cells by B cells in the context of major
histocompatibility complex (MHC) II molecules, resulting in B-cell help by the responding
T cells. The activated B cells undergo antibody class switching to IgG and are then able to
secrete high levels of anti-polysaccharide antibodies. The development of memory B cells
speciﬁc for the polysaccharide antigen is also initiated e this is the key to providing long-term
immune protection, as seen with the highly protective Hib, meningococcal and
pneumococcal conjugate vaccines.
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Figure 3.8 The principles underpinning polysaccharide conjugate vaccines. Polysaccharide antigens alone are weakly immunogenic, eliciting
only a transient antibody response (panel A). Vaccines consisting of polysaccharides conjugated to proteins (panel B) elicit a greater antibody
response and long-term memory including T cells, which are not generated with polysaccharide antigens alone. The immune response to such
vaccines is illustrated in the charts within the boxed panel: the red lines illustrate the relatively low and transient production of B cells and
antibodies in response to polysaccharide vaccines and the lack of a T-cell response, whereas polysaccharide conjugate vaccines produce
a higher quantity of B and T cells and antibodies which are sustained for longer.
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An important consideration in vaccine
design is deﬁning what a vaccine should
prevent e infection or consequences
of infection, ie disease. The majority
of vaccines prevent disease and
not infection.
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particulate antigens
Recombinant protein-DNA techniques make possible the
production of highly pure proteins from pathogens. Several of
these recombinant proteins, once harvested from the expression
system and puriﬁed, aggregate in particulate antigens, which are
more immunogenic than soluble antigens due to the way in which
they interact with APCs. The enhanced ability of the innate immune
system to recognise these types of structures is probably intrinsic
rather than related to the speciﬁc antigen per se. This approach
has been successfully applied in licensed vaccines for HBV and
HPV, and in a candidate malaria vaccine currently in Phase III
clinical trials.CASE STUDY 3 Recombinant proteins for the HBV vaccine antigen and beyond
The natural immune response to HBV involves the production of interferons by T cells and
production of antibodies by B cells, in response to various components of the viral particle.
Antibodies against the HBV surface protein are neutralising and protective against future
infection, hence the levels of these antibodies are a serological correlate of protection. This
protein (hepatitis B surface antigen [HBsAg]) was therefore selected as the antigen for the
HBV vaccine. The antigen was initially derived from the plasma of chronic HBV carriers, but
this plasma-derived vaccine presented certain issues from the perspective of supply
depending on chronic HBV carrier donors, and also because of the risk (or fear of the risk) of
transmission of blood-borne infections (although this was remote). It was not practical to use
a classical subunit approach to developing non-infectious antigens, as HBV does not grow
efﬁciently in cell culture. As a result, a recombinant protein approach was used to generate
highly puriﬁed HBsAg for the vaccine (see Figures 3.3 and 3.6 for schematic representations
of recombinant approaches to vaccine antigens).
The gene encoding HBsAg was sequenced to allow antigen production by recombinant DNA
techniques in yeast expression systems. HBsAg was the ﬁrst vaccine antigen to be
manufactured through recombinant DNA technology, and represented a new and high
degree of purity of a single protein antigen in a vaccine. This antigen was also the ﬁrst to
demonstrate that recombinant proteins can self-assemble into a particulate structure.
Continued on next page
The recombinant HBsAg protein adjuvanted with aluminium salt provides high levels of
protection in immune-competent individuals and is a highly effective vaccine. However, in
immune-compromised individuals, who respond less well to HBsAg vaccination, doubled
dosages and multiple administrations are needed to ensure protective immunity, and some
individuals fail to respond even after repeated immunisations. Alternative formulations were
developed and studied, resulting in an HBV vaccine containing a new adjuvant combination:
Adjuvant System (AS) 04 (see Chapter 4 e Vaccine adjuvants). The vaccine was developed
speciﬁcally for use in pre-haemodialysis/haemodialysis patients, who respond poorly to the
conventional vaccine and are at increased risk of HBV infection.
An additional application of the recombinant HBsAg has been the development of one of the
more promising candidate malaria vaccines to date, RTS,S. This approach uses peptides
from the malaria circumsporozoite (CS) protein (called RT), expressed as a hybrid matrix
particle with the HBsAg and incorporated into a self-assembling complex e a presentation
that enhances antigen recognition and processing by the immune system. This is delivered
with a proprietary adjuvant combination, AS01 (see Chapter 4 e Vaccine adjuvants). The RT
portion includes both the CS repetitive B-cell (antibody-inducing) epitopes, as well as
portions of non-repeat regions that had been identiﬁed as T-cell determinants. The candidate
induces high levels of cytokines involved in Th1-biased T-cell activation. This candidate
vaccine is now in Phase III trials after having shown protection in earlier clinical studies.
CASE STUDY 4 Recombinant antigens for vaccines against HPV and the VLP concept
Cervical cancer is a major killer of women worldwide caused by persistent cervical mucosal
infection with oncogenic strains of HPV. HPV infections do not cause lysis of infected cells,
thus avoiding initiation of inﬂammatory responses. The virus life cycle does not include
a blood-borne phase, further limiting exposure of viral antigens to the immune system.
Despite the attenuation of the immune response, however, the majority of naturally acquired
HPV infections are cleared by cellular and humoral effectors, although natural immune
responses following infection do not reliably protect against repeated HPV infection,
particularly against different strains of HPV. Natural exposure (infection) therefore does
not eliminate the risk of a subsequent HPV infection or the development of a persistent
Continued on next page
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infection e a key step in the development of cervical cancer. Hence, in order to protect
women throughout their lifetime, a vaccine must improve on natural immunity, eg immunity
resulting from infection.
HPV presents a challenge for vaccination, which needs to induce a systemic adaptive
immune response to a virus that enters and remains localised at the mucosal level. Preclinical
studies showed that high levels of protection relied on the production of high levels of
HPV-speciﬁc neutralising antibodies in the serum directed against the L1 surface protein,
probably because they can transude/exude to the local cervical/vaginal mucosa. The
successful HPV vaccine strategy that has been developed takes account of both the
pathogenesis of infection and features of the host immune system. The antigen consists of
a surface protein from HPV (L1 protein) that spontaneously assembles into empty capsid
virus-like particles (VLPs). The protein is produced using recombinant DNA technology
in yeast or insect cells (see Figure 3.6). The VLPs, which resemble the native virus, when
combined with an adjuvant, are capable of inducing stronger and more protective immune
responses than those resulting from infection.
Using this approach in the two licensed vaccines against HPV has provided an opportunity to
protect against the major cause of cervical cancer.
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Targets of immune protection have been identiﬁed in many
pathogens, knowledge of which is driving future vaccine design
(Table 3.3). In addition to identifying targets of protection, many
more challenges remain for vaccines, which are discussed in
Chapter 6e Vaccines of the future. These include tackling emerging
pathogens and pathogens that display wide antigenic diversity,
and populations with speciﬁc needs. In addition to identifying
vaccine antigens against infectious diseases, in the last decade
research has been intensiﬁed in order to ﬁnd ways to develop
vaccine-like immunotherapies against chronic disorders such
as type I diabetes, Alzheimer’s disease and cancer e where
inﬂuencing the immune responses against speciﬁc antigens may
play a role in prevention or cure. To address these challenges, new
innovative methods of vaccine antigen design are being actively
researched and developed.
TABLE 3.3. EXAMPLES OF KNOWN TARGETS OF IMMUNE
PROTECTION
Pathogen Targets of immune protection
Inﬂuenza HA, NA
Pertussis Pertussis toxoid
Pertactin
FHA
Fimbriae
HPV L1
Tetanus
Diphtheria
Toxoids
HBV HBsAg
Hib
Pneumococcus
Meningococcus
Typhoid
Polysaccharides of the surface capsule of speciﬁc types
HA, haemagglutinin; NA, neuraminidase; FHA, ﬁlamentous haemagglutinin;
HPV, human papillomavirus; HBV, hepatitis B virus; HBsAg, hepatitis B surface
antigen; Hib, Haemophilus inﬂuenzae type b. Every effort has been made to
verify the information in this table. The information included is not meant to be
exhaustive but to give an overview of the subject matter.
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Advances in fundamental sciences such as immunology, as well as
cell biology, genomic and proteomic technologies, may offer new
avenues for vaccine development. The potential for increased
pathogen attenuation, via elimination or the attenuation/modiﬁcation/
substitution of genes responsible for virulence, could allow us to
selectively silence these key pathogenic determinants, while
retaining the immunogenic and innate defensive signals. Broader
application of reverse vaccinology may also lead to rational selection
of antigenic components based on the hypotheses and theories that
attempt to understand the workings of the immune system, while
eliminating deleterious pathogenic products, resulting in extremely
pure antigens of greater immunogenicity. Many future vaccines are
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antigens, due to the pathogenic and antigenic complexities of the
remaining unconquered infectious agents (including HIV, hepatitis C
virus, RSV,Mycobacterium tuberculosis; see Chapter 6e Vaccines of
the future). Where protective mechanisms are known or can be
predicted, we are increasingly able to selectively induce these, using
the most appropriate approach as outlined in this chapter.
Understanding mechanisms of action of natural defence-triggering
molecules has stimulated the design of new vaccine adjuvants that
mimic natural responses to infection (see Chapter 4 e Vaccine
adjuvants). The advances in vaccine technology have initiated
a future of novel and innovative vaccine designs based on new
knowledge of the antigenic properties of pathogens and the ways in
which a protective immune response might be induced.
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